Dyne Therapeutics, Inc. (NASDAQ:DYN) disclosed that an entity connected to Dirk Kersten sold a combined 337,248 shares of the company’s common stock, producing aggregate proceeds of $6,815,190, according to a recent Form 4 filing.
The filings show two separate transactions on April 17 and April 20, 2026, with reported weighted average sale prices spanning $20.0672 to $20.2916 per share.
Transaction details
On April 17, the Form 4 records indicate 211,974 shares were sold at a weighted average price of $20.2916 per share. The filing notes that individual sale prices on that date ranged from $20.00 to $20.75, and that this block of shares generated approximately $4,301,008.
Three days later, on April 20, an additional 125,274 shares changed hands at a weighted average price of $20.0672 per share. The April 20 sales are reported with individual sale prices in the range of $21.00 to $21.20 and produced roughly $2,514,000 in proceeds.
Ownership and the trading plan
The Form 4 indicates both sales were executed indirectly by ForDyne B.V. and were made pursuant to a Rule 10b5-1 trading plan. That plan was adopted by ForDyne B.V. on November 11, 2025. The shares sold are held directly by ForDyne B.V., which the filing describes as an entity jointly owned by Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund II Cooperatief U.A.
Mr. Kersten is identified in the filing as a partner of Forbion Management and a member of its investment committee, and also as a partner of FGO II Management and a member of its investment committee. The filing states that he disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest.
Following the reported sales, the indirect holdings attributed to Mr. Kersten decreased to 4,207,525 shares of Dyne Therapeutics common stock.
Analyst commentary reflected in filings
The disclosure arrives alongside a summary of analyst activity noting that several firms have reiterated positive ratings on Dyne’s stock amid its clinical progress. H.C. Wainwright maintained a Buy rating with a $50.00 price target after discussions with Dyne’s management about the regulatory path for Duchenne muscular dystrophy. Raymond James kept a Strong Buy rating and a $40.00 price target, referencing preliminary data from a related program at Sarepta Therapeutics.
Baird reiterated an Outperform rating with a $30.00 price target and cited confidence in Dyne’s clinical progress and an improved regulatory environment. Jones Trading maintained a Buy rating with a $35.00 target after updates on Dyne’s exon 51 skipper for Duchenne muscular dystrophy, which the firm described as showing promising results. Stifel reiterated a Buy rating with a $39.00 price target and highlighted the design of Dyne’s phase 3 confirmatory study in myotonic dystrophy type 1.
These analyst actions, as reported in the filing, reflect ongoing attention to Dyne Therapeutics tied to its research and clinical programs.
What the filing shows and does not show
The Form 4 documents the mechanics of the sales, the parties holding the shares, the trading plan under which the transactions were conducted, and the post-transaction indirect share count attributed to Mr. Kersten. The filing does not provide additional commentary from the company or the listed funds, nor does it contain any statements about future transactions or intentions beyond the disclosed trades and the adopted 10b5-1 plan.